At a glance
ClinicalIndex Comparison RecordN/ACompleted· 227 enrolled
Drug / intervention
sildenafil citratedrug
Likely dose
sildenafil citrate 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Jun 3, 2011·Updated Feb 1, 2021
In Brief
An observational study evaluating sildenafil citrate for Pulmonary Arterial Hypertension. Completed, enrolled 227 participants across 2 sites in 2 countries.
Detailed Summary
The objective of this observational study is to gain clinical insight on the actual use of sildenafil citrate (Revatio™) for the treatment of pulmonary arterial hypertension (PAH). The primary objective is to assess effectiveness and safety of sildenafil at doses ≥20mg three times daily for the treatment of PAH.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesGermany, Ireland
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Enrollment StartJul 2011
Primary CompletionOct 2011
TodayJul 2026
First PostedJun 3, 2011
Enrollment StartJul 1, 2011
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 15.1 years ago
Interventions
sildenafil citratedrug
Sildenafil citrate, 20mg oral tablets, taken at least three times daily